This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cattaneo, M. Articles by Gachet, C. Search for Related Content PubMed PubMed Citation Articles by Cattaneo, M. Articles by Gachet, C. Related Collections Coagulation and fibronolysis Platelets Mechanism of atherosclerosis/growth factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2281-2285.)
© 1999 American Heart Association, Inc.

Brief Review

ADP Receptors and Clinical Bleeding Disorders

Marco Cattaneo; Christian Gachet

From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center (M.C.), IRCCS Ospedale Maggiore, University of Milano, Milano, Italy, and INSERM U.311 (C.G.), Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France.

Correspondence to Marco Cattaneo, MD, Hemophilia and Thrombosis Center, University of Milano, Via Pace 9, 20122 Milano, Italy. E-mail marco.cattaneo{at}unimi.it

	Abstract

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
Abstract—ADP plays a key role in hemostasis and thrombosis. Despite its early identification in 1961 as the first known aggregating agent, the molecular basis of ADP-induced platelet activation is only beginning to be understood. The present review proposes a model of 3 purinergic receptors contributing separately to the complex process of ADP-induced platelet aggregation: the P2X₁ ionotropic receptor, responsible for rapid influx of ionized calcium into the cytosol; the P2Y₁ metabotropic receptor, responsible for mobilization of ionized calcium from internal stores, which initiates aggregation; and an as-yet-unidentified P2Y receptor coupled to G_i2, which is essential for the full aggregation response to ADP. It is probable that this as-yet-unidentified receptor is the molecular target of the ADP-selective antiaggregating drugs ticlopidine and clopidogrel. In addition, it is probably defective in patients with a bleeding diathesis that is characterized by selective impairment of platelet responses to ADP.

Key Words: adenosine diphosphate • purino receptors • platelets • bleeding disorders • thrombosis

	Introduction

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
ADP, the first known low-molecular-weight, platelet-aggregating agent, was initially identified after observations that a small molecule derived from red blood cells stimulated platelet adhesion to glass and induced platelet aggregation.^{1 2} Adenine nucleotides, which originate from platelet dense granules and damaged cells, especially red blood cells and endothelial cells, interact with P2 receptors to regulate a broad range of physiological processes. P2 receptors are widely distributed in many different cell types. These receptors are divided into 2 main groups: the G protein–coupled, or "metabotropic," superfamily termed P2Y and the ligand-gated ion channel, or "ionotropic," superfamily termed P2X.³ Seven subtypes of P2X and 11 subtypes of P2Y receptor have been identified to date.

Several lines of evidence indicate that ADP plays a key role in the formation of the hemostatic plug and in the pathogenesis of arterial thrombi: (1) ADP is contained at high concentrations in the platelet dense granules and is released when platelets are stimulated by other agents, such as thrombin or collagen, thus reinforcing platelet aggregation⁴ ; (2) inhibitors of ADP-induced platelet aggregation are effective antithrombotic drugs^{5 6} ; and (3) patients with defects of ADP receptors or those lacking ADP in platelet granules have a bleeding diathesis.^{4 7}

	ADP-Induced Platelet Activation

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
Addition of exogenous ADP to washed human platelets results in shape change, reversible aggregation at physiological concentrations of ionized calcium in the external medium, and finally, desensitization. In a minority of individuals, the close platelet-to-platelet contact brought about by the aggregation process triggers the formation of trace amounts of thromboxane A₂, which stimulates platelet secretion and reinforces aggregation.⁸ This effect is greatly enhanced⁹ and can be observed in most individuals⁸ when the concentration of ionized calcium in the extracellular medium is artifactually decreased to the micromolar level, such as in citrated, platelet-rich plasma.

Transduction of the ADP-induced signal involves inhibition of adenylyl cyclase and a concomitant transient rise in free cytoplasmic calcium, due to both calcium influx and mobilization of internal calcium stores.^{1 2} ADP also induces a unique and extremely rapid influx of calcium from the extracellular medium, which has been attributed to ligand-gated calcium channels.^{1 2} In addition, it has been found to activate G_i2, which could explain how it inhibits adenylyl cyclase.^{1 2}

The recent demonstration that platelets from knockout mice lacking the gene coding for the q subunit of the Gq protein do not aggregate in response to ADP¹⁰ indicates that the phospholipase C pathway is necessary to raise intracellular calcium levels after ADP stimulation and that this step is essential to platelet aggregation. On the other hand, inhibition of adenylyl cyclase is a key feature of platelet activation by ADP but displays no causal relationship to aggregation. Moreover, this effect of ADP can be observed only when adenylyl cyclase has been prestimulated by prostaglandins or other activators.^{1 2} Thus, ADP triggers at least 2 biochemical events in platelets, a phospholipase C–mediated rise in intracellular calcium and a G_i2-mediated inhibition of adenylyl cyclase. Whether 1 or more ADP receptors are responsible for these effects has been a challenging debate over the past 30 years, and the question now appears close to resolution.

	Agonists, Antagonists, and Inhibitors

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
Purinoceptor pharmacology presently lacks specific and selective agonists and antagonists to discriminate clearly between receptor subtypes. The originality of platelet ADP receptors lies in the fact that while ADP is the natural agonist, ATP is a competitive antagonist of all effects of ADP on platelets except the very fast calcium entry, which seems to be triggered by both molecules.^{1 2} A platelet ADP receptor was previously defined on the basis of pharmacological data as the receptor responsible for ADP-induced aggregation, intracellular calcium increases, and adenylyl cyclase inhibition.^{1 2} This receptor was termed P2T, where T denotes thrombocytes and was presumed to be lineage specific.

One may classify agonists and antagonists into 2 main families: full agonists and antagonists, which stimulate or inhibit both calcium mobilization and inhibition of stimulated adenylyl cyclase, and partial agonists and antagonists, which preferentially stimulate or inhibit calcium mobilization or cyclase inhibition. Some analogues of ADP are of interest on account of their preferential action on stimulated adenylyl cyclase, while others, such as adenosine 5'-O-(1-thiodiphosphate) (ADPS), act on platelet aggregation without affecting adenylyl cyclase. Thus, 2-methylthioadenosine 5'-diphosphate (2-MeSADP) is 200-fold more potent than ADP as an inhibitor of adenylyl cyclase but only 5-fold more potent as an aggregating agent.¹ Certain nonhydrolyzable analogues, like 2-methylthioadenosine 5'-ß,-methylenetriphosphonate (2-MeSAMP-PCP) and 2-ethylthioadenosine 5'-monophosphate (2-EtSAMP), competitively inhibit the action of ADP on adenylyl cyclase and inhibit platelet aggregation induced by ADP or ADPS (which inhibits stimulated adenylate cyclase) but do not inhibit platelet aggregation induced by ADPS (which has no effect on stimulated adenylate cyclase). Adenosine 3'-phosphate 5'-phosphosulfate (A3P5PS), adenosine 2',5'-diphosphate (A2P5P), and adenosine 3',5'-diphosphate (A3P5P) inhibit platelet aggregation to ADP by competitively antagonizing the intracellular calcium rise induced by this agonist.^{11 12 13 14} These AMP analogues, known to be selective P2Y₁ receptor antagonists,¹ had, on the contrary, no effect on adenylyl cyclase inhibition.

The thienopyridine compounds ticlopidine and clopidogrel, 2 specific and potent inhibitors of ADP-induced platelet aggregation, are used clinically as antithrombotic drugs.⁵ These drugs, which are inactive in vitro and must be metabolized in the liver to acquire their antiaggregating properties, selectively antagonize the ADP-induced inhibition of prostaglandin E₁–activated adenylyl cyclase but do not modify other effects of ADP on platelets, including shape change and calcium movements. They cause a dose-dependent reduction in the number of 2-MeSADP binding sites on platelets.^{1 15} Under conditions where the 2-MeSADP binding sites are maximally reduced (up to 70% reduction) and ADP-induced aggregation and inhibition of adenylyl cyclase are completely blocked by thienopyridine treatment, low concentrations of ADP can still promote platelet shape change and a rise in intracellular calcium. Such findings point to the existence of a platelet ADP receptor insensitive to thienopyridines and responsible for shape change and calcium signaling.

In contrast to thienopyridines, ATP analogues like AR-C66096 are direct inhibitors of ADP-induced platelet activation in vitro. Although no binding data are as yet available, the molecular target of AR-C66096 seems to be very similar to that of the thienopyridine compounds.¹¹

Measurements of the binding of [³³P]2-MeSADP to the platelets of a patient (V.R.) with a congenital deficiency of ADP-induced aggregation thought to be related to a receptor defect¹⁶ revealed a reduction of up to 70% in the number of binding sites compared with control platelets, without modification of the binding affinity (see below).¹⁵ Interestingly, the clinical profile and platelet functions of this patient are the same as when thienopyridines are administered to humans or animals. The main feature is a strong and selective inhibition of the aggregation response to ADP, despite conserved shape change. At the intracellular level, ADP-induced responses are blocked, with the exception of the intracellular calcium rise, as after thienopyridine treatment.

The above findings may be interpreted on the basis of 2 principal ADP receptors on blood platelets: 1 coupled to calcium mobilization and necessary to initiate ADP-induced aggregation and 1 coupled to adenylyl cyclase, responsible for amplification of the response. Probably, this latter receptor is defective in patients with congenital impairment of platelet responses to ADP and is the molecular target of thienopyridines.

	Molecular Identity of the Platelet ADP Receptors

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
Attempts to clone a platelet-specific ADP receptor by using megakaryoblastic cell lines as sources for a cDNA library have to date been unsuccessful. However, several P2 purinoceptors have been cloned in human erythroleukemia (HEL) cells, in particular the P2Y₁ receptor, which was the first P2 purinoceptor to be cloned, originally from a chick brain cDNA library.¹⁷ After the human endothelial P2Y₁ receptor was cloned and sequenced, P2Y₁ mRNA was found to be present in megakaryoblastic cell lines (HEL, MEG-01, Dami, CHRF-288, and K562) and in human platelets.¹⁸ After its stable expression in Jurkat cells, the human P2Y₁ receptor proved to be an ADP receptor at which Sp-ATPS and ATP were competitive antagonists, and partial agonistic responses to triphosphate nucleotides were found to be due to degradation of the commercial reagents into diphosphate nucleotides.¹⁸ These studies were extended to platelets and to brain capillary endothelial cells expressing the P2Y₁ receptor, and it was shown that the agonistic responses of purified triphosphate nucleotides were due to enzymatic transformation into diphosphate analogues by ectonucleotidases present at the surface of the cells.¹⁹

These results supported the hypothesis that the P2Y₁ receptor could be the elusive P2T receptor. Nevertheless, the fact that the selective P2Y₁ antagonists A2P5P and A3P5P inhibited ADP-induced platelet aggregation but had no effect on ADP-induced adenylyl cyclase inhibition led to the suggestion that another as-yet-unidentified receptor must mediate this effect of ADP on platelets.^{11 12 13 14 20 21} The suggestion was later strongly supported by the demonstration, at both genetic and pharmacological levels, that the P2Y₁ receptor was normal in a patient (V.R.) with congenital impairment of platelet responses to ADP.²² This receptor should be of the P2Y type, since ADP is known to activate the G_i2 heterotrimeric G protein in human platelet membranes.² It also should exhibit a pharmacological profile identical to that of the P2Y₁ receptor but with subtle differences in the selectivity of certain ligands and should be the molecular target of thienopyridines²³ and the direct antagonist AR-C66096. Unfortunately to date, no such receptor appears to have been cloned.

Apart from the now-well-characterized P2Y₁ receptor and the putative P2Y receptor coupled to G_i2, a P2X₁ receptor could be responsible for the fast calcium entry induced by ADP in human platelets. Polymerase chain reaction amplification of human cDNA with oligonucleotides specific for the human P2X₁ purinoceptor subtype demonstrated the presence of P2X₁ transcripts in platelets and megakaryoblastic cell lines, whereas the selective P2X₁ agonist ß-MeATP was found to trigger a calcium influx into fura 2–loaded human platelets.²⁴ These findings confirmed the existence of functional P2X₁ purinoceptors on blood platelets. However, because ß-MeATP does not induce platelet shape change, aggregation, or phospholipase C activation and because desensitization of the P2X₁ receptor is without effect on ADP-induced aggregation, the physiological role of P2X₁ receptors on platelets remains unclear and would in fact seem to be discrete.^{11 23}

In conclusion, at least 3 distinct ADP receptors seem to be involved in the complex process of platelet activation and aggregation: the P2X₁ ionotropic receptor, the role of which remains to be established; the P2Y₁ receptor, which is necessary to initiate ADP-induced shape change and aggregation through calcium mobilization but not sufficient to support a full platelet response; and a P2Y receptor coupled to G_i2, which is essential for the full aggregation response of platelets to ADP.^{11 12 13 14 20 21 25}

	Congenital Defects of Platelet ADP Receptor(s)

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
In 1992, the first patient (V.R.) with a selective defect of platelet responses to ADP was described.¹⁶ He is a man of white origin, aged 49 years at the time of diagnosis, who had a lifelong history of excessive bleeding, prolonged bleeding time, and an abnormality of platelet aggregation that was similar to that observed in patients with defects of platelet secretion (reversible aggregation in response to weak agonists and impaired aggregation in response to low concentrations of collagen or thrombin), except that the aggregation response to ADP was severely impaired. This platelet aggregation profile is the same one that occurs when thienopyridines are administered to humans and is compatible with a selective impairment of responses to ADP, which also affects the full aggregation response to release-inducing agonists, as a consequence of the loss of the potentiating effect of released ADP on platelet aggregation. Other abnormalities of platelet function found in this patient were common to those induced by thienopyridine compounds, including (1) no inhibition by ADP of prostaglandin E₁–stimulated platelet adenylyl cyclase but normal inhibition by epinephrine; (2) normal shape change and normal (or only mildly reduced) mobilization of cytoplasmic ionized calcium induced by ADP; and (3) the presence of 30% of the normal number of platelet binding sites for [³³P]2-MeSADP (see above). Three additional patients, 1 male²⁶ and 2 females,²⁷ with very similar characteristics were subsequently described; in 1 of them, it was shown that the ADP receptor pathway that is defective in this condition is linked to a selective tyrosine phosphorylation response.²⁸ The many similarities among the patients suggest that they are affected by the same type of disorder of platelet function, probably associated with defective interaction between ADP and the P2Y receptor that is coupled to G_i2.⁷ The functional defects of these patients could result from (1) a quantitative or qualitative defect of the receptor or (2) a permanently downregulated, nonfunctional protein.²⁶ Similarities between these patients and humans or animals that were treated with clopidogrel have been reported in terms of the morphology of ADP-induced platelet aggregates²⁹ as well as in signal transduction studies.³⁰

The defect is probably inherited as an autosomal recessive trait, because all patients so far described were born of consanguineous parents. The son of 1 of them, who is considered to be an obligate heterozygote, bound intermediate levels of 2-MeSADP.³¹ His bleeding time was mildly prolonged (13 minutes), and his platelets underwent a normal first wave of aggregation after stimulation with ADP but did not secrete normal amounts of ATP after stimulation with different agonists. The secretion defect of his platelets could not be ascribed to impaired production of thromboxane A₂ or low concentrations of platelet granule contents, which were normal, and are therefore similar to that of platelets with the so-called primary secretion defect (PSD). PSD is the most common congenital defect of platelet secretion and is characterized by a normal primary wave of aggregation induced by ADP and other agonists, a normal concentration of platelet granule contents, and normal production of thromboxane A₂.⁴ Because PSD patients also have a moderately decreased number of platelet-binding sites for 2-MeSADP,³¹ it is likely that they are heterozygous for the severe defect of the platelet ADP receptor that is coupled to Gi2 and that the full complement of platelet-binding sites for ADP is necessary for full platelet secretion. Studies of normal platelets that had been pretreated with acetylsalicylic acid and stimulated under nonstirring conditions to avoid the formation of large aggregates indicated that ADP potentiates platelet secretion directly and independently of platelet aggregation and the production of thromboxane A₂.³¹ The role of ADP in potentiating platelet secretion has been recently confirmed in studies of platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients.³²

The Congenital Defect in Platelet ADP Receptor(s) as a Model to Study the Role of Released ADP in Platelet Function
With the use of platelets from patient V.R., it was possible to demonstrate that ADP plays a role in the stabilization of thrombin-induced platelet aggregates³³ and contributes to shear-induced platelet aggregation³⁴ but that it does not play an essential role in platelet aggregation and fibrinogen binding induced by the prostaglandin endoperoxide-thromboxane A₂ mimetic U46619.³⁵

Therapy
The intravenous infusion of the vasopressin analogue DDAVP (0.3 µg/kg body weight) shortened the prolonged bleeding time of patient V.R. from 20 minutes to 8.5 minutes.³⁴ After the infusion of DDAVP, which was repeated twice at 24-hour intervals, the patient underwent a surgical intervention for herniated disc repair, which was not complicated by excessive bleeding. Although the efficacy of DDAVP in reducing bleeding complications of patients with defects of primary hemostasis is anecdotal, its administration is generally without serious side effects and can therefore be recommended for the prophylaxis and treatment of bleeding episodes in these patients.

	Conclusions

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
Although itself a weak platelet-aggregating agent, ADP is a key platelet agonist. At least 3 distinct ADP receptors are involved in the complex process of platelet activation and aggregation: the P2X₁ ionotropic receptor, the role of which remains to be established; the P2Y₁ receptor, which is necessary to initiate ADP-induced aggregation through calcium mobilization but not sufficient to support a full platelet response; and a P2Y receptor coupled to G_i2, which is essential for the full aggregation response of platelets to ADP. This latter receptor seems to be defective in patients with congenital defects of platelet responses to ADP and the target of thienopyridine compounds. The antithrombotic effects of these latter compounds and the bleeding diathesis that is associated with the congenital defect of this receptor further emphasize the critical role of the ADP amplification pathway in hemostasis and thrombosis.

Note Added in Proof
It was recently shown that platelets from P2Y1 receptor knockout mice do not aggregate in response to ADP and aggregate poorly in response to collagen; in contrast, inhibition of adenylyl cyclase by ADP is preserved (Léon C, Hechler B, Vial C, Freund M, Ohlmann P, Dierich A, LeMeur M, Cazenave J-P, Gachet C. Platelets from P2Y1 receptor knockout mice do not aggregate in response to ADP. Thromb Haemost. 1999; (suppl):421. These data unambiguously demonstrate the existence of a platelet ADP receptor distinct from P2Y1. The demonstration that P2Y1 receptor knockout mice are resistant to the thromboembolism induced by the intravenous injection of ADP or collagen suggests that P2Y1 represents a potential target for antithrombotic drugs.

View larger version (38K): [in this window] [in a new window]   Figure 1. Schematic representation of the current model of ADP-induced platelet activation. Two ADP receptors have been firmly identified in blood platelets: a P2X1 receptor, responsible for a unique rapid influx of calcium into the cytosol, and the P2Y1 receptor, responsible for intracellular calcium mobilization, shape change, and initiation of aggregation. Another P2Y receptor coupled to adenylyl cyclase inhibition would appear to mediate the amplification of platelet aggregation induced by ADP and the potentiation of platelet secretion. In addition, it is likely that this as-yet-unidentified receptor is the molecular target of the ADP-specific antiplatelet thienopyridine drugs and is defective in patients with a bleeding diathesis that is characterized by selective impairment of platelet responses to ADP. PLC indicates phospholipase C; AC, adenylyl cyclase.

Received February 8, 1999; accepted March 11, 1999.

	References

Top Abstract Introduction ADP-Induced Platelet Activation Agonists, Antagonists, and... Molecular Identity of the... Congenital Defects of Platelet... Conclusions References

 
1. Mills DC. ADP receptors on platelets. Thromb Haemost. 1997;76:835–856.

2. Gachet C, Hechler B, Leon C, Vial C, Leray C, Ohlmann P, Cazenave JP. Activation of ADP receptors and platelet function. Thromb Haemost. 1997;78:271–275.[Medline] [Order article via Infotrieve]

3. Bhagwat SS, William M. P2 purine and pyrimidine receptors: emerging superfamilies of G-protein-coupled and ligand-gated ion channel receptors. Eur J Med Chem. 1997;32:183–193.

4. Rao AK. Congenital disorders of platelet function. In: Colman RW, Rao AK, eds. Platelets in Health and Disease: Hematol/Oncol Clin North Am.. 1990;4:65–82.

5. Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4:252–261.

6. Humphries RG, Robertson MJ, Leff P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci. 1995;16:179–181.[Medline] [Order article via Infotrieve]

7. Cattaneo M. Hereditary defect of the platelet ADP receptor(s). Platelets. 1998;8:161–164.

8. Falcon CR, Cattaneo M, Ghidoni A, Mannucci PM. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionised calcium. Thromb Haemost. 1993;70:389–392.[Medline] [Order article via Infotrieve]

9. Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol. 1975;228:1757–1765.[Abstract/Free Full Text]

10. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in Gq-deficient mice. Nature. 1997;389:183–186.[Medline] [Order article via Infotrieve]

11. Daniel JL, Dangelmaier CA, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation, I: evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273:2024–2029.[Abstract/Free Full Text]

12. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998;422:291–295.[Medline] [Order article via Infotrieve]

13. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y₁ receptor is necessary for ADP-induced platelet aggregation. Blood.. 1998;92:152–159.[Abstract/Free Full Text]

14. Geiger J, Honig-Liedl P, Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol. 1998;351:235–246.[Medline] [Order article via Infotrieve]

15. Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, Cazenave J-P. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol. 1995;91:434–444.[Medline] [Order article via Infotrieve]

16. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992;80:2787–2796.[Abstract/Free Full Text]

17. Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, Burnstock G, Barnard EA. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett. 1993;324:219–223.[Medline] [Order article via Infotrieve]

18. Leon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y₁ receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett. 1997;403:26–30.[Medline] [Order article via Infotrieve]

19. Hechler B, Vigne P, Leon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y₁ receptor: similarities with the platelet ADP receptor. Mol Pharmacol. 1998;53:727–733.[Abstract/Free Full Text]

20. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation, II: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998;273:2030–2034.[Abstract/Free Full Text]

21. Jantzen H-M, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, Conley PB. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost. 1999;81:111–117.[Medline] [Order article via Infotrieve]

22. Léon C, Vial C, Gachet C, Ohlmann P, Hechler B, Cazenave JP, Lecchi A, Cattaneo M. The P2Y₁ receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost.. 1991;81:775–781.

23. Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y₁ receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol. 1998;103:858–866.[Medline] [Order article via Infotrieve]

24. Vial C, Hechler B, Leon C, Cazenave JP, Gachet C. Presence of P2X₁ purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost. 1997;78:1500–1504.[Medline] [Order article via Infotrieve]

25. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A. 1998;95:8070–8074.[Abstract/Free Full Text]

26. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest. 1995;95:1612–1622.

27. Cattaneo M, Zighetti ML, Lombardi R, Lecchi A, Gachet C, Cazenave J-P, Mannucci PM. Platelets from a patient heterozygous for the deficiency of 2 MeS-ADP binding sites have a secretion defect. Eur J Clin Invest. 1997;27(suppl 1):A23. Abstract.

28. Levy-Toledano S, Maclouf J, Rosa JP, Gallet C, Valles G, Nurden P, Nurden AT. Abnormal tyrosine phosphorylation linked to a defective interaction between ADP and its receptors on platelets. Thromb Haemost. 1998;80:463–468.[Medline] [Order article via Infotrieve]

29. Humbert M, Nurden P, Bihour C, Pasquet JM, Winckler J, Heilmann E, Savi P, Herbert JM, Kunicki TJ, Nurden AT. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol. 1996;16:1532–1543.[Abstract/Free Full Text]

30. Savi P, Artçanuthurry V, Bornia J, Grelac F, Maclouf J, Levy-Toledano S, Herbert J-M. Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets. Br J Haematol. 1997;97:185–191.[Medline] [Order article via Infotrieve]

31. Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave J-P, Mannucci PM. Deficiency of [³³P]2 MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production: evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost. 1997;77:986–990.[Medline] [Order article via Infotrieve]

32. Polgar J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood. 1998;91:549–554.[Abstract/Free Full Text]

33. Cattaneo M, Canciani MT, Lecchi A, Kinlough-Rathbone RL, Packham MA, Mannucci PM, Mustard JF. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood. 1990;75:1081–1086.[Abstract/Free Full Text]

34. Cattaneo M, Zighetti ML, Lombardi R, Mannucci PM. Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP. Br J Haematol. 1994;88:826–829.[Medline] [Order article via Infotrieve]

35. Cattaneo M, Randi AM, Canciani MT, Lecchi A, Mannucci PM. Role of ADP in platelet aggregation and fibrinogen binding induced by prostaglandin endoperoxides: studies in a patient with selective defect of ADP-induced platelet aggregation. In: Jamieson GA, ed. Platelet Membrane Receptors: Molecular Biology, Immunology, Biochemistry and Pathology. New York, NY: Alan R. Liss; 1988:279–283.

This article has been cited by other articles:

				M. Cattaneo Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I33 - I37. [Abstract] [Full Text] [PDF]

				M. Cattaneo, A. Lecchi, M. L. Zighetti, and F. Lussana Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count Haematologica, May 1, 2007; 92(5): 694 - 697. [Abstract] [Full Text] [PDF]

				H. Shankar, B. N. Kahner, J. Prabhakar, P. Lakhani, S. Kim, and S. P. Kunapuli G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases Blood, November 1, 2006; 108(9): 3027 - 3034. [Abstract] [Full Text] [PDF]

				V L Serebruany, M G Midei, H Meilman, A I Malinin, and D R Lowry Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad. Med. J., June 1, 2006; 82(968): 404 - 410. [Abstract] [Full Text] [PDF]

				S. Murugappan, H. Shankar, S. Bhamidipati, R. T. Dorsam, J. Jin, and S. P. Kunapuli Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKC{delta} in platelets Blood, July 15, 2005; 106(2): 550 - 557. [Abstract] [Full Text] [PDF]

				A. Coppola, L. Coppola, L. dalla Mora, F. M. Limongelli, A. Grassia, L. Mastrolorenzo, G. Gombos, and G. Lucivero Vigorous exercise acutely changes platelet and B-lymphocyte CD39 expression J Appl Physiol, April 1, 2005; 98(4): 1414 - 1419. [Abstract] [Full Text] [PDF]

				M. Chhatriwala, R. G. Ravi, R. I. Patel, J. L. Boyer, K. A. Jacobson, and T. K. Harden Induction of Novel Agonist Selectivity for the ADP-Activated P2Y1 Receptor Versus the ADP-Activated P2Y12 and P2Y13 Receptors by Conformational Constraint of an ADP Analog J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1038 - 1043. [Abstract] [Full Text] [PDF]

				M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]

				N. S. Kleiman Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1989 - 1991. [Full Text] [PDF]

				P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-Loza, J.-L. Reny, M. Aiach, and P. Gaussem Adenosine Diphosphate-Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects Circulation, August 26, 2003; 108(8): 989 - 995. [Abstract] [Full Text] [PDF]

				T. R. Kyriakides, P. Rojnuckarin, M. A. Reidy, K. D. Hankenson, T. Papayannopoulou, K. Kaushansky, and P. Bornstein Megakaryocytes require thrombospondin-2 for normal platelet formation and function Blood, May 15, 2003; 101(10): 3915 - 3923. [Abstract] [Full Text] [PDF]

				M. A. van Gestel, J. W.M. Heemskerk, D. W. Slaaf, V. V.T. Heijnen, R. S. Reneman, and M. G.A. oude Egbrink In Vivo Blockade of Platelet ADP Receptor P2Y12 Reduces Embolus and Thrombus Formation but Not Thrombus Stability Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 518 - 523. [Abstract] [Full Text] [PDF]

				M. Cattaneo, M. L. Zighetti, R. Lombardi, C. Martinez, A. Lecchi, P. B. Conley, J. Ware, and Z. M. Ruggeri Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding PNAS, February 18, 2003; 100(4): 1978 - 1983. [Abstract] [Full Text] [PDF]

				S. Goto, N. Tamura, K. Eto, Y. Ikeda, and S. Handa Functional Significance of Adenosine 5'-Diphosphate Receptor (P2Y12) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ib{alpha} Induced by Conditions of High Shear Rate Circulation, May 28, 2002; 105(21): 2531 - 2536. [Abstract] [Full Text] [PDF]

				M. Cattaneo, C. Gachet, J.-P. Cazenave, M. A. Packham ;, J. Jin, T. M. Quinton, J. Zhang, S. E. Rittenhouse, and S. P. Kunapuli Adenosine diphosphate (ADP) does not induce thromboxane A2 generation in human platelets Blood, May 15, 2002; 99(10): 3868 - 3870. [Full Text] [PDF]

				P. Lova, S. Paganini, F. Sinigaglia, C. Balduini, and M. Torti A Gi-dependent Pathway Is Required for Activation of the Small GTPase Rap1B in Human Platelets J. Biol. Chem., March 29, 2002; 277(14): 12009 - 12015. [Abstract] [Full Text] [PDF]

				N. A. Turner, J. L. Moake, and L. V. McIntire Blockade of adenosine diphosphate receptors P2Y12 and P2Y1 is required to inhibit platelet aggregation in whole blood under flow Blood, December 1, 2001; 98(12): 3340 - 3345. [Abstract] [Full Text] [PDF]

				B. Hechler, P. Toselli, C. Ravanat, C. Gachet, and K. Ravid Mpl Ligand Increases P2Y1 Receptor Gene Expression in Megakaryocytes with No Concomitant Change in Platelet Response to ADP Mol. Pharmacol., November 1, 2001; 60(5): 1112 - 1120. [Abstract] [Full Text] [PDF]

				B. Nieswandt, W. Bergmeier, A. Eckly, V. Schulte, P. Ohlmann, J.-P. Cazenave, H. Zirngibl, S. Offermanns, and C. Gachet Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation Blood, June 15, 2001; 97(12): 3829 - 3835. [Abstract] [Full Text] [PDF]

				C. Leon, M. Freund, C. Ravanat, A. Baurand, J.-P. Cazenave, and C. Gachet Key Role of the P2Y1 Receptor in Tissue Factor-Induced Thrombin-Dependent Acute Thromboembolism : Studies in P2Y1-Knockout Mice and Mice Treated With a P2Y1 Antagonist Circulation, February 6, 2001; 103(5): 718 - 723. [Abstract] [Full Text] [PDF]

				F. Di Virgilio, P. Chiozzi, D. Ferrari, S. Falzoni, J. M. Sanz, A. Morelli, M. Torboli, G. Bolognesi, and O. R. Baricordi Nucleotide receptors: an emerging family of regulatory molecules in blood cells Blood, February 1, 2001; 97(3): 587 - 600. [Abstract] [Full Text] [PDF]

				M.-P. Gratacap, J.-P. Herault, C. Viala, A. Ragab, P. Savi, J.-M. Herbert, H. Chap, M. Plantavid, and B. Payrastre Fcgamma RIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation Blood, November 15, 2000; 96(10): 3439 - 3446. [Abstract] [Full Text] [PDF]

				M. Cattaneo, A. Lecchi, R. Lombardi, C. Gachet, and M. L. Zighetti Platelets From a Patient Heterozygous for the Defect of P2CYC Receptors for ADP Have a Secretion Defect Despite Normal Thromboxane A2 Production and Normal Granule Stores : Further Evidence That Some Cases of Platelet 'Primary Secretion Defect' Are Heterozygous for a Defect of P2CYC Receptors Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20 (11): e101 - e106. [Abstract] [Full Text] [PDF]

				P. Ohlmann, A. Eckly, M. Freund, J.-P. Cazenave, S. Offermanns, and C. Gachet ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galpha q Blood, September 15, 2000; 96(6): 2134 - 2139. [Abstract] [Full Text] [PDF]

				C. Oury, E. Toth-Zsamboki, C. Van Geet, C. Thys, L. Wei, B. Nilius, J. Vermylen, and M. F. Hoylaerts A Natural Dominant Negative P2X1 Receptor Due to Deletion of a Single Amino Acid Residue J. Biol. Chem., July 21, 2000; 275(30): 22611 - 22614. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cattaneo, M. Articles by Gachet, C. Search for Related Content PubMed PubMed Citation Articles by Cattaneo, M. Articles by Gachet, C. Related Collections Coagulation and fibronolysis Platelets Mechanism of atherosclerosis/growth factors